True Rheumatic Emergencies · Episode 01
Giant Cell Arteritis: The Vision Came Back. What Happens Next?
A grey curtain. Ten minutes. Then normal vision. Follow the decisions that come next in a teaching case of suspected giant cell arteritis.
Listen
Three points to keep
- A visual symptom that resolves can still signal a time-critical problem.
- When GCA is strongly suspected with threatened vision, treatment and diagnostic confirmation move together.
- A normal blood test, an initially negative study, or improvement in headache cannot by itself establish that vision is safe. New visual symptoms need urgent reassessment, even after treatment has started.
Episode script
Imagine a seventy-two-year-old woman at breakfast. A grey curtain drops over her right eye. Ten minutes later, it lifts.
By the time you see her, she can read the clock on the wall.
“It went away,” she says. “So I almost didn’t come.”
The vision has returned. The question is whether the danger has passed.
This is RheumaView. Today: giant cell arteritis, and a warning that can disappear before the patient reaches your door.
You ask a few more questions. She has a new ache around one temple. Her scalp hurts when she brushes her hair. And lately, her jaw gets tired and painful halfway through a meal. Resting makes it better.
She thought that last problem belonged to her dentist.
Now the story has changed. In this older patient, transient visual loss together with these symptoms makes giant cell arteritis a serious concern. We’ll call it G C A.
But keep your diagnostic field wide. Sudden loss of vision in one eye can also signal retinal ischemia from another cause. If retinal or cerebral ischemia is suspected, activate the emergency stroke pathway alongside the eye assessment. Giving steroids does not complete the evaluation.
So what happens next?
Arrange urgent ophthalmology assessment that day, as soon as possible. Ongoing or worsening visual loss requires immediate emergency care. Contact the receiving team directly. Make sure someone knows what happened, when it started, and where the patient is going.
An “urgent” label on a referral does not make the phone ring.
While help is being arranged, clarify the event. Which eye? A dark curtain, blurring, double vision, or a missing part of the visual field? How long? Any recurrence? Check vision in each eye separately if you can do so without delaying care. One functioning eye can conceal a major problem in the other.
Now comes the decision that matters most.
When G C A is strongly suspected and vision is threatened, start high-dose glucocorticoids immediately. Arrange diagnostic confirmation in parallel. The biopsy appointment and the ultrasound slot must not become reasons to leave the patient untreated.
For newly diagnosed G C A with threatened vision, the American College of Rheumatology and Vasculitis Foundation conditionally favor intravenous pulse treatment. The evidence that intravenous treatment is better than oral treatment is very uncertain, so the decision requires urgent clinical judgment.
If intravenous treatment cannot begin promptly, start appropriate high-dose oral treatment while arranging specialist care. The British guideline makes this point explicitly: waiting for an infusion must not delay treatment.
This is a monitored emergency treatment plan. Glucose, blood pressure, infection risk, and the patient’s other illnesses still matter. The aim is to prevent further ischemic injury. Established visual loss may not recover.
What about the blood tests?
Obtain a blood count with platelets, a sedimentation rate, and C-reactive protein, ideally before treatment if that causes no delay.
Raised inflammatory markers can support the diagnosis. Normal results do not rule it out. And in a patient already receiving tocilizumab, a low C-reactive protein can be particularly misleading: flares can occur with normal inflammatory markers.
A reassuring laboratory result cannot overrule a concerning visual history.
We still need to establish the diagnosis. Prompt, reliable testing matters, because the consequences of both missing G C A and treating the wrong diagnosis are substantial.
European guidance recommends expert ultrasound of the temporal and axillary arteries as the first imaging test. The American guideline favors temporal artery biopsy in its practice setting. Local expertise and access help determine the route. Treatment can change imaging findings, so arrange testing promptly and record when steroids began.
If the first test is negative but the clinical picture remains concerning, reassess. A single result may not settle the case.
Return to our patient.
She is still reading the clock. That is useful information about this moment. The ten-minute blackout remains important information about what happened earlier.
Her next step is urgent assessment, treatment when warranted, and diagnostic confirmation. Someone also needs to own the next day: review the results, reassess vision, plan continuing treatment, and explain exactly how to get help if symptoms recur.
Three things to take away.
First: a visual symptom that resolves can still signal a time-critical problem.
Second: when G C A is strongly suspected with threatened vision, treatment and diagnostic confirmation move together.
Third: a normal blood test, an initially negative study, or improvement in headache cannot by itself establish that vision is safe. New visual symptoms need urgent reassessment, even after treatment has started.
For the examination checklist, treatment details, and diagnostic pitfalls, open Giant Cell Arteritis with Threatened Vision in the free Professional Essentials at dr dot RheumaView dot com. You’ll find the sources and links to the full clinical guide there.
The vision came back. Now make sure the next decision protects it.
Sources and further reading
The clinical discussion draws on the following guidance and studies.
- American College of Rheumatology/Vasculitis Foundation guideline (2021): diagnosis and treatment of giant cell arteritis, including threatened vision.
- British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis (2020): urgent assessment and treatment pathways.
- EULAR recommendations for imaging in large vessel vasculitis: 2023 update (published in 2024): the role of ultrasound and other imaging.
- Kermani et al.: utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis: interpretation of inflammatory markers.
- Stone et al.: glucocorticoid dosages and acute-phase reactant levels at GCA flare in a randomized trial of tocilizumab (2019): inflammatory markers during relapse.
- American Heart Association: management of central retinal artery occlusion (2021): retinal ischemia and emergency stroke assessment.
Take the reasoning further
Explore the examination checklist, treatment details, and diagnostic pitfalls in Giant Cell Arteritis with Threatened Vision · Professional Essentials. Free, no registration.